CDMO Market Overview

Market opportunity
Increase in outsourcing to CDMOs by 2025
Cell and gene therapy outsourced market
Of M&A activity
since 2021

Investment Thesis

Kineticos believes the $40+ billion outsourced market will continue to expand with a growing number of therapeutic companies seeking services. This comes at a time of a service disconnect; for example, in cell and gene therapy – a Kineticos’ area of investment – there is simply not enough capacity and poor service offerings.

New From Kineticos

Press Release
July 26, 2023

Kincell Bio Launches

Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies RALEIGH, N.C., AND…

Press Release
November 30, 2022

Experic Closes $14 Million Series B Financing

Experic, a contract development and manufacturing organization (CDMO) and clinical supply services company serving the biopharmaceutical industry, today announced the…

Press Release
February 18, 2022

Recipharm Acquires Arranta Bio

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio.